SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Compensation Committee approved special equity grants to Steven M. Rales and Mitchell P. Rales on July 31, 2026, comprising non-qualified stock options (1,000,000 shares each) and restricted stock units (500,000 shares each) with four- to five-year vesting as part of a Long-Term Growth Program.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Champion Homes' 2026 Annual Meeting of Shareholders held on July 30, 2026, covering three proposals: election of six directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the core content of the filing, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →Innovex International disclosed Q2 2026 quarterly financial results via press release, reporting revenue of $245 million (up 9% year-over-year), net income of $25 million, adjusted EBITDA of $48 million, and free cash flow of $30 million, along with forward guidance for Q3 2026.
View raw filing on EDGAR →Cabot Corporation issued a press release on August 3, 2026 announcing operating results for its fiscal quarter ended June 30, 2026, disclosing third quarter diluted EPS of $0.12 and Adjusted EPS of $1.67, along with segment EBIT results and updated fiscal 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, the designated item for results of operations and financial condition.
View raw filing on EDGAR →ASE Technology announced the pricing of a US$1 billion offering of Currency Linked Zero Coupon Convertible Bonds due 2031. This constitutes creation of a new direct financial obligation — a material debt issuance. The proceeds are designated for subsidiary capital contributions, repayment of existing borrowings, and purchase of materials, indicating a significant financing event material to investors.
View raw filing on EDGAR →The filing discloses the resignation of two directors, Leon Chen, Ph.D. and Joshua Wolfe, effective July 31, 2026. This is a clear departure event under Item 5.02. The explicit statement that the resignations were not due to disagreement with the Company does not diminish the materiality of the departure itself—changes in board composition are material to investors' assessment of governance and oversight.
View raw filing on EDGAR →The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.
View raw filing on EDGAR →Atlas Energy Solutions issued a press release on August 3, 2026 disclosing second quarter 2026 financial results, including total revenue of $293.2 million, net loss of $25.1 million, and Adjusted EBITDA of $49.5 million.
View raw filing on EDGAR →TripAdvisor has entered into a definitive Equity Purchase Agreement to sell its TheFork restaurant reservation and management platform business to American Express Travel Related Services Company for $700 million in an all-cash transaction. The filing discloses execution of the binding agreement on August 2, 2026, following completion of required French labor consultation, making this a material disposition of a significant business segment that would substantially affect the registrant's operations and financial position.
View raw filing on EDGAR →Intuitive Machines completed the acquisition of Goonhilly Earth Station Limited (UK-based ground station company) for £37.0 million in cash and stock, and COMSAT LLC (US-based satellite communications provider) for a base purchase price of $10 million. These material acquisitions expand the company's deep space communications capabilities and ground station network for lunar and space missions.
View raw filing on EDGAR →The Company filed a prospectus supplement on August 3, 2026 under its at-the-market (ATM) offering program with Cantor Fitzgerald, authorizing the offer and sale of up to $200,000,000 of common stock. This is a dilutive equity issuance under an ATM facility, which is material to investors as it signals potential capital raising and shareholder dilution. The filing of the prospectus supplement activates the offering authority and represents a material capital markets event.
View raw filing on EDGAR →Obsidian Therapeutics completed a merger with Galera Therapeutics effective August 3, 2026, resulting in a combined company operating under the Obsidian name and trading on Nasdaq under ticker 'OBX'. The transaction included a concurrent $350 million private placement financing, with resulting ownership of approximately 51.6% Legacy Obsidian shareholders, 1.2% Legacy Galera shareholders, and 47.2% new PIPE investors.
View raw filing on EDGAR →Obsidian Therapeutics completed an unregistered private placement of $350 million in equity securities concurrent with the merger closing, with investors including Balyasny Asset Management, Caligan Partners, and Eventide Asset Management acquiring approximately 47.2% of the combined company's outstanding common stock.
View raw filing on EDGAR →KPMG LLP was appointed as the independent registered public accounting firm for Obsidian Therapeutics, approved by the Board on August 3, 2026, effective upon completion of the merger transaction.
View raw filing on EDGAR →Amendments to the certificate of incorporation and bylaws of Obsidian Therapeutics became effective immediately prior to and upon completion of the merger, including a name change to 'Obsidian Therapeutics, Inc.', authorization of 500 million common shares and 10 million preferred shares, elimination of written consent rights, and establishment of advance notice procedures for stockholder proposals.
View raw filing on EDGAR →The filing discloses a declaration by the Board of Directors of a regular quarterly cash dividend of $0.375 per share, payable on September 8, 2026, to stockholders of record as of August 24, 2026. This is a straightforward dividend distribution announcement, which is material to investors as it affects shareholder returns and capital allocation decisions.
View raw filing on EDGAR →The filing discloses the appointment of Myriam J. Curet, M.D. as a new Class II director to Mobia's Board, effective July 30, 2026, increasing the Board size from seven to eight members. Dr. Curet brings substantial medical and board experience from senior roles at Intuitive Surgical and current directorships at Inspire Medical Systems and Stereotaxis, Inc. This is a material governance event affecting board composition and leadership.
View raw filing on EDGAR →The 6-K body explicitly states that "Attached as Exhibit I hereto is a copy of the press release of Capital Clean Energy Carriers Corp. announcing the financial results for the second quarter ended June 30, 2026." This is a discrete earnings announcement for Q2 2026, which is material to investors assessing the registrant's financial performance and is classified as an earnings_release event.
View raw filing on EDGAR →Lantheus Holdings entered into an Agreement and Plan of Merger with Curium US Holdings LLC on August 3, 2026, whereby Lantheus will merge with and into a subsidiary of Curium, with Lantheus surviving as a wholly owned subsidiary of Curium. The merger consideration is $102.50 per share in cash plus contingent value rights up to $12.00 per share, representing a material change of control transaction.
View raw filing on EDGAR →Lantheus disclosed compensatory arrangements for named executive officers in connection with the pending merger, including transaction bonuses totaling $6.0 million and amendments to severance letter agreements for five named executive officers clarifying treatment of converted PSU awards and eligibility for earned 2026 bonuses upon qualifying terminations.
View raw filing on EDGAR →Jersey Mike's Subs Inc. entered into multiple material definitive agreements in connection with its initial public offering on July 29, 2026, including a restructured LLC agreement, tax receivable agreement, exchange agreement, registration rights agreement, and stockholders agreement with Blackstone affiliates, fundamentally restructuring the company's capital and governance in connection with the change of control from private to public ownership.
View raw filing on EDGAR →Matthew Bromberg was appointed to the Board of Directors effective July 29, 2026, following the IPO, with compensatory arrangements including a director retainer and RSU award.
View raw filing on EDGAR →Jersey Mike's completed an IPO on July 31, 2026, issuing 43,478,261 shares of Class A Common Stock at $21.85 per share, raising approximately $950 million gross, with $301 million of net proceeds used to retire debt.
View raw filing on EDGAR →Material modifications to rights of security holders were disclosed in connection with the IPO, with details incorporated from Item 5.03 regarding amendments to articles of incorporation and bylaws.
View raw filing on EDGAR →Galera Therapeutics completed a merger with Legacy Obsidian (via Gazelle Parent, Inc., which renamed itself Obsidian Therapeutics, Inc.) effective August 3, 2026. The transaction resulted in a change of control, with Legacy Obsidian shareholders holding 51.6% of the combined entity, PIPE investors 47.2%, and Galera shareholders 1.2%, with approximately 61.7 million shares outstanding post-merger. The merger included a Contingent Value Rights Agreement establishing post-closing contingent consideration tied to future product development and divestiture proceeds.
View raw filing on EDGAR →Item 3.03 discloses a material modification to the rights of security holders, but the filing excerpt contains only cross-references to other Items without substantive detail of the specific modification.
View raw filing on EDGAR →Dr. Stephen W. Hales retired from the Board effective immediately on July 29, 2026, after twenty-two years of service. While the filing also mentions Mark Romig's appointment to Chair the Nominating/Governance Committee, the principal disclosed action is the departure of a director. The retirement is material as it represents a significant change in board composition after more than two decades of service.
View raw filing on EDGAR →Park Ha Biological Technology entered into a securities purchase agreement on August 3, 2026, to issue 10,000,000 Class A ordinary shares plus warrants to purchase 2,000,000 additional shares to non-U.S. investors for approximately US$1.8 million in gross proceeds. The securities were offered and sold in offshore transactions in reliance on Regulation S, a classic private placement structure. This is a dilutive equity issuance that raises capital and increases share count materially.
View raw filing on EDGAR →The 6-K discloses that Ellomay's 10 MW solar facility in Italy (51% owned) was successfully connected to the national grid and commenced energy production on July 30, 2026, with expected annual production of approximately 16.5 GWh/year. This is a material operational milestone—the transition from construction to commercial operation of a significant renewable energy asset—that would affect a reasonable investor's assessment of the company's project development progress and revenue-generating capacity, but does not fit a more specific event category (not M&A, not a financial result, not a restructuring).
View raw filing on EDGAR →Erke Huang resigned as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, and Director of WhiteFiber, Inc., effective August 1, 2026. Justin Zhu was appointed as his replacement CFO, and Huang transitioned to a Senior Advisor role.
View raw filing on EDGAR →Justin Zhu resigned as Senior Vice President of Finance and Chief Accounting Officer effective August 1, 2026. This is a departure of a named executive officer responsible for critical financial and accounting functions. While the resignation was orderly and not due to disagreement, the loss of the principal accounting officer is material to investors' assessment of the company's financial reporting and governance.
View raw filing on EDGAR →Can-Fite announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, representing the company's first clinical program for this rare genetic disease. This is a material operational and strategic milestone—the initiation of a new clinical development program in a high-need therapeutic area with no approved treatments—but does not fit the specific event categories of earnings release, M&A, executive changes, or other named types. The disclosure reflects a significant expansion of the company's pipeline and development strategy.
View raw filing on EDGAR →The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These material C-suite appointments strengthen the company's leadership structure for global expansion and commercialization of its drug pipeline as multiple Phase III registrational studies advance.
View raw filing on EDGAR →The press release announces that Hub Cyber Security has regained full compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement of $35 million after receiving a deficiency notice on January 21, 2026. The Nasdaq Staff confirmed on July 31, 2026 that the Company had maintained the required threshold for 20 consecutive business days and the matter is now closed. This disclosure directly addresses a delisting risk that previously threatened the Company's continued listing on Nasdaq.
View raw filing on EDGAR →This is an ASX application for quotation of 408,839,531 ordinary fully paid shares issued on 3 August 2026 as Tranche 1 of an Australian placement at AUD 0.015 per share. The document references a prior Appendix 3B announcement dated 24 July 2026 describing a "Proposed issue of securities" placement. This represents a material dilutive equity issuance raising approximately AUD 6.1 million, with additional tranches and warrants yet to be issued to complete the transaction, typical of a capital raise by a smaller biotech company.
View raw filing on EDGAR →This press release announces a material clinical development milestone: submission of a Clinical Trial Notification (CTN) to Australia's TGA and HREC approval to commence a Phase I clinical trial for AN4035, a first-in-class pan-RAS(ON) ADC. The company also notes that IND submissions to the U.S. FDA and China NMPA are in process, with patient dosing expected in H2 2026. For a clinical-stage biopharmaceutical company, advancement of a lead therapeutic candidate into human clinical trials is a material operational and strategic event that would affect a reasonable investor's assessment of the company's progress and pipeline value.
View raw filing on EDGAR →TNL Mediagene's Board has established a special committee of independent directors to evaluate "potential strategic transactions and alternatives," explicitly including "a financing, recapitalization, merger, business combination, share issuance, disposition or other strategic transaction." The company has engaged Imperial Capital as financial advisor to "identify and evaluate transactions that would maximize value for shareholders." This announcement of a formal process to explore material M&A activity or strategic alternatives is a significant disclosure that would affect a reasonable investor's assessment of the company's future direction and value.
View raw filing on EDGAR →This press release discloses POMDOCTOR's strategic business structure and operational direction—a four-tier diversified revenue model spanning B2C healthcare services, AI-enabled chronic disease subscriptions, B2B enterprise services, and pharmaceutical real-world data services. While the disclosure includes historical revenue figures (RMB399.9M in FY2025), it is primarily a strategic announcement of the company's integrated healthcare ecosystem and technology expansion plans rather than a discrete earnings release or financial results announcement. The material nature reflects that this articulates the company's forward-looking operational strategy and business model evolution, which would affect a reasonable investor's assessment of the registrant's growth trajectory and competitive positioning.
View raw filing on EDGAR →Clearmind Medicine announced entry into a non-binding Letter of Intent to acquire a 51% majority stake in an EV wireless charging solutions company for $2.5 million, plus a $1.5 million loan. This constitutes a material acquisition activity under Item 1.01 (entry into a material acquisition agreement), even though the LOI is non-binding and closing is subject to definitive agreements and due diligence. The transaction represents a significant strategic shift for a clinical-stage biotech company and would materially affect investor assessment.
View raw filing on EDGAR →This exhibit announces a strategic cooperation memorandum of understanding (MOU) between Jingxing HK (an indirect subsidiary of Reitar) and Cainiao Group for global smart warehousing and automated logistics solutions. The disclosure details a framework for joint business development, technology collaboration, and procurement arrangements, with specific near-term projects in Spain and the Netherlands. While the MOU is explicitly characterized as a non-binding framework document without unconditional procurement commitments, the announcement of a material strategic partnership with a major logistics technology company (Cainiao Group) and the identification of concrete near-term projects with anticipated September 2026 deliveries would affect a reasonable investor's assessment of the company's growth prospects and operational strategy. This is an operational/strategic business event rather than a discrete M&A transaction, making operational_other the most appropriate classification.
View raw filing on EDGAR →The 6-K discloses the appointment of Nancy Yang as an independent director, chairman of the compensation committee, and member of the audit and nominating committees effective August 1, 2026. While the filing also mentions the concurrent resignation of Heung Ping Wong, the primary substantive action disclosed is Ms. Yang's appointment to the Board with specific committee assignments and qualifications as an audit committee financial expert. This is material as it affects Board composition and governance structure.
View raw filing on EDGAR →La Rosa entered into a Securities Purchase Agreement on July 31, 2026, to issue 150 shares of Series E Convertible Preferred Stock at $1,000 per share for $150,000 in gross proceeds. This private placement of convertible preferred equity securities to an institutional investor is dilutive to existing shareholders.
View raw filing on EDGAR →La Rosa Holdings issued a press release on August 3, 2026, announcing financial results for the fiscal quarter ended March 31, 2026, including revenue of $13.6M, gross profit of $2.0M (up 29.6% YoY), operating loss of $2.5M (improved 46.5% YoY), cash position, and digital asset holdings of $8.1M, along with condensed consolidated balance sheets and statements of operations.
View raw filing on EDGAR →The filing discloses completion of the previously announced acquisition of MaintainX Inc. pursuant to a merger agreement dated May 28, 2026. Completion of a material acquisition is a core M&A event that would materially affect a reasonable investor's assessment of the registrant's capital deployment, strategic direction, and financial position.
View raw filing on EDGAR →Air Industries Group amended its Amended and Restated Agreement and Plan of Merger with Tenax Aerospace Acquisition, LLC on July 31, 2026, extending the Outside Date from September 30, 2026 to November 30, 2026 to accommodate SEC review of the S-4 registration statement for the pending business combination.
View raw filing on EDGAR →Bluerock Acquisition Corp. entered into a definitive Business Combination Agreement with Yellow.ai (Bitonic Technology Labs Inc.), with the combined company valued at approximately $550 million pro forma equity value and expected to close in H2 2026 subject to shareholder approval. The transaction constitutes a material acquisition and change of control, with Yellow.ai becoming a wholly-owned subsidiary of the domesticated Bluerock.
View raw filing on EDGAR →Bluerock Acquisition Corp. disclosed unregistered sales of equity securities in connection with PIPE Investments, with $30 million of committed PIPE financing from institutional investors relying on Section 4(a)(2) and Regulation D exemptions as part of the merger transaction.
View raw filing on EDGAR →The 6-K discloses the dismissal of MaloneBailey, LLP as the Company's independent registered public accounting firm effective August 3, 2026, and the concurrent appointment of Deloitte & Touche LLP as the new auditor. The filing explicitly states "CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT" and provides detailed disclosures regarding the prior auditor's reports, any disagreements, and reportable events, consistent with Item 16F(a) of Form 20-F requirements for auditor changes.
View raw filing on EDGAR →The filing discloses that Hashdex Commodities Trust (Hashdex Bitcoin ETF, ticker DEFI) has authorized a plan to liquidate the Fund, terminate its continuous offering, and deregister its shares under Section 12(b) of the Exchange Act. Trading will be suspended after August 17, 2026, and the Fund will be delisted from NYSE Arca following a Form 25 filing. This is a terminal delisting event driven by the sponsor's decision to close the fund due to low assets under management ($14.7 million) and operational considerations.
View raw filing on EDGAR →The disclosure centers on operational and strategic business developments: a monthly robotics sales record (152 units in July, 394 cumulative for the year), the launch of the "Built in USA" Acceleration Program in response to the FCC's new policy restricting foreign-produced advanced robotic devices, and a preview of an industry partner recruitment conference. While the FCC policy creates a regulatory tailwind and competitive advantage, the core event is the company's operational response—accelerating localized production and ecosystem deployment—rather than a specific financial, governance, or legal trigger. This is material to investors as it signals market opportunity and strategic positioning in the robotics sector.
View raw filing on EDGAR →